title: Hemostasis associated with abnormalities of fibrinolysis.
abstract: Hemostatic plugs consist of platelet aggregates and fibrin mesh containing blood cells and plasma components. Hemostatic efficiency depends on the rate of formation of hemostatic plugs as well as the structural integrity and stability of the formed hemostatic plugs. Fibrin elements are major constituents contributing to the structural integrity and stability, but they are subject to fibrinolytic activity occurring spontaneously after fibrin formation. Fibrinolysis is usually suppressed by endogenous inhibitors. Increase of a profibrinolytic component or deficiency of an inhibitor would result in an accelerated fibrinolysis, causing a premature lysis of hemostatic plugs before restoration of injured vessels, leading to a hemorrhagic tendency. Such a state can be seen typically in patients with congenital deficiency of alpha 2-plasmin inhibitor or a hereditary increase of plasminogen activator, and it is also seen in acquired situations such as amyloidosis, liver cirrhosis, disseminated intravascular coagulation (particularly in patients with acute promyelocytic leukemia) and thrombolytic therapy. The hemorrhagic tendency can be well controlled by an administration of an antifibrinolytic agent: epsilon-aminocaproic acid or tranexamic acid. In contrast to an accelerated fibrinolysis causing a hemorrhagic tendency, retarded fibrinolysis may predispose an individual to a thrombotic tendency. Retarded fibrinolysis may be due to either an increase in plasminogen activator inhibitors or decrease of plasminogen activators. Quantitative or qualitative deficiency of plasminogen may also lead to a thrombotic tendency.
authors.affiliation: First Department of Medicine, Tokyo Medical and Dental University School of Medicine, Japan.
authors.forename: N
authors.initials: N
authors.lastname: Aoki
mesh_terms: D000933:Antifibrinolytic Agents / Q000627:therapeutic use; D005342:Fibrinolysis / Q000187:drug effects*; D006474:Hemorrhagic Disorders / Q000188:drug therapy*; D006487:Hemostasis; D006801:Humans; D013927:Thrombosis / Q000188:drug therapy
chemical_list: D000933:Antifibrinolytic Agents